Page 45 - 2025中醫藥與天然藥物聯合學術研討會-中醫藥與天然藥物的挑戰Ｘ機遇與未來大會手冊

From Genes to Immunity: Pharmacogenomics and Immune Profiling for

Drug Discovery

,1
Wei-Chiao Chang*

1 Department of Clicinal Pharmacy, Taipei Medical University, Taipei, Taiwan

* E-mail: wcc@tmu.edu.tw

Abstract
The integration of biobank resources and NGS has transformed precision medicine by
enabling large-scale analysis of HLA polymorphisms, pharmacogenomic variants, and T-cell

receptor (TCR) repertoires. The HLA profiles are essential for presenting peptide antigens to T
cells, influencing immune response, drug hypersensitivity, and cancer immunotherapy. Through
high-resolution HLA typing and NGS, population-based studies identify genetic factors shaping
immunity and treatment response. Pharmacogenomics complements this by identifying variants
affecting drug efficacy and toxicity, supporting personalized therapy. In oncology, integrated

analysis of tumor exome, HLA genotype, and TCR sequencing allows prediction of neoantigens
that can elicit cytotoxic T-cell responses. These discoveries enable the design of personalized
cancer vaccines, offering new strategies for precise cancer immunotherapy. Together,

pharmacogenomics and immune profiling are building the foundation for precision therapy and
drug discovery.

23